Research programme: humanised fusion proteins - Protox

Drug Profile

Research programme: humanised fusion proteins - Protox

Alternative Names: HUMxin platform; HUMxin Programme

Latest Information Update: 09 Apr 2012

Price : $50

At a glance

  • Originator Medicenna Ventures
  • Developer Sophiris Bio
  • Class
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 Apr 2012 Discontinued for Cancer in Canada (unspecified route)
  • 02 Apr 2012 Protox Therapeutics is now called Sophiris Bio
  • 23 Aug 2007 Early research in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top